tetano
Editor, Senior Moderator
J Med Virol
. 2021 Nov 27.
doi: 10.1002/jmv.27481. Online ahead of print.
Meta-analysis of arbidol versuslopinavir/ritonavir in the treatment of coronavirus disease 2019
Miao Yu[SUP] 1 [/SUP], Deng-Chao Wang[SUP] 2 [/SUP], Sheng Li[SUP] 1 [/SUP], Yue-Hua Lei[SUP] 2 [/SUP], Jian Wei[SUP] 2 [/SUP], Li-Yan Huang[SUP] 3 [/SUP]
Affiliations
Abstract
Objectives: To systematically evaluate the efficacy and safety of Arbidol and lopinavir/ritonavir (LPV/r) in the treatment of coronavirus disease 2019(COVID-19) using a meta-analysis method.
Methods: The China Knowledge Network, VIP database, WanFang database PubMed database, Embase database, and Cochrane Library were searched for a collection of comparative studies on Arbidol and lopinavir/ritonavir in the treatment of coronavirus disease 2019. Meta-analysis was used to evaluate the efficacy and safety of Arbidol and lopinavir/ritonavir in the treatment of COVID-19.
Results: The results of the systematic review indicated that Arbidol had a higher positive-to-negative conversion rate of SARS-CoV-2 nucleic acid on Day 7 [P=0.03], a higher positive-to-negative conversion rate of SARS-CoV-2 nucleic acid on Day 14 [P=0.006], a higher improvement rate of chest CT on Day 14 [P=0.02], a lower incidence of adverse reactions [P=0.002] and lower rate of mortality[P=0.007]. There was no difference in the rate of cough disappearance on Day 14 [P=0.24] or the rate of severe/critical illness [P=0.07] between the two groups.
Conclusions: Arbidol may be superior tolopinavir/ritonavir in the treatment of COVID-19. However, due to the small number of included studies and the number of patients, high-quality multi-centre large-sample randomized double-blind controlled trials are still needed for verification. This article is protected by copyright. All rights reserved.
Keywords: Arbidol; coronavirus disease 2019; lopinavir/ritonavir; meta-analysis.
. 2021 Nov 27.
doi: 10.1002/jmv.27481. Online ahead of print.
Meta-analysis of arbidol versuslopinavir/ritonavir in the treatment of coronavirus disease 2019
Miao Yu[SUP] 1 [/SUP], Deng-Chao Wang[SUP] 2 [/SUP], Sheng Li[SUP] 1 [/SUP], Yue-Hua Lei[SUP] 2 [/SUP], Jian Wei[SUP] 2 [/SUP], Li-Yan Huang[SUP] 3 [/SUP]
Affiliations
- PMID: 34837230
- DOI: 10.1002/jmv.27481
Abstract
Objectives: To systematically evaluate the efficacy and safety of Arbidol and lopinavir/ritonavir (LPV/r) in the treatment of coronavirus disease 2019(COVID-19) using a meta-analysis method.
Methods: The China Knowledge Network, VIP database, WanFang database PubMed database, Embase database, and Cochrane Library were searched for a collection of comparative studies on Arbidol and lopinavir/ritonavir in the treatment of coronavirus disease 2019. Meta-analysis was used to evaluate the efficacy and safety of Arbidol and lopinavir/ritonavir in the treatment of COVID-19.
Results: The results of the systematic review indicated that Arbidol had a higher positive-to-negative conversion rate of SARS-CoV-2 nucleic acid on Day 7 [P=0.03], a higher positive-to-negative conversion rate of SARS-CoV-2 nucleic acid on Day 14 [P=0.006], a higher improvement rate of chest CT on Day 14 [P=0.02], a lower incidence of adverse reactions [P=0.002] and lower rate of mortality[P=0.007]. There was no difference in the rate of cough disappearance on Day 14 [P=0.24] or the rate of severe/critical illness [P=0.07] between the two groups.
Conclusions: Arbidol may be superior tolopinavir/ritonavir in the treatment of COVID-19. However, due to the small number of included studies and the number of patients, high-quality multi-centre large-sample randomized double-blind controlled trials are still needed for verification. This article is protected by copyright. All rights reserved.
Keywords: Arbidol; coronavirus disease 2019; lopinavir/ritonavir; meta-analysis.